Tevogen Bio Entered Into A Binding Term Sheet With An Existing Investor To Secure Up To $50M Of Financing
Supports expansion of Tevogen's ExacTcell™ platform toward additional clinical trials Bolsters a financial path to positive cashflow and minimizes dilutionWARREN, N.J., May 10, 2024 (GLOBE NEWSWIRE) --